ReviewNon-coding RNA research2024
Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.
Review in Non-coding RNA research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Cancer-Derived Exosomes: A Cross-Cancer Comparative Analysis of Exosomal Proteins and MicroRNAs.International journal of molecular sciences · 2026Review
- The updated role of exosomes in cancer diagnosis and therapy.Discover oncology · 2026Review
- LncRNA expression in prostate cancer: FromNon-coding RNA research · 2026Article
- Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and In Silico Characterization.Life (Basel, Switzerland) · 2026Article
- Role of Exosomal Non-Coding RNAsMicroRNA (Shariqah, United Arab Emirates) · 2026Review
- Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.The journal of liquid biopsy · 2025Review
- Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management.Cancers · 2025Review
- A branching bivariate weibull distribution model for evaluating exosomes in androgen-deprived agency in the presence of prostate cancer.Scientific reports · 2025Article
- The impact of SRRM2-AS1 in ovarian cancer: a comprehensive analysis based on pan-cancer and in vitro validation.Discover oncology · 2025Article
- Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics.Cancers · 2025Review
- Exosomal ncRNAs in reproductive cancers†.Biology of reproduction · 2025Review
- Suppression of TP Rat Pancreatic Acinar Cell Apoptosis by hucMSC-Ex Carrying hsa-miR-21-5p via PTEN/PI3K Regulation.Stem cells international · 2025Article
- Prognostic Impact of H19/Cell Adhesion Molecules Circuitry on Prostate Cancer Biopsy.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) has the highest frequency of diagnosis among solid tumors and ranks second as the primary cause of cancer-related deaths. Non-coding RNAs (ncRNAs), such as microRNAs, long non-coding RNAs and circular RNAs, frequently exhibit dysregulation and substantially impact the biological behavior of PCa. Compared with circulating ncRNAs, ncRNAs loaded into exosomes are more stable because of protection by the lipid bilayer. Furthermore, exosomal ncRNAs facilitate the intercellular transfer of molecules and information. Increasing evidence suggests that exosomal ncRNAs hold promising potential in the progression, diagnosis and prognosis of PCa. This review aims to discuss the functions of exosomal ncRNAs in PCa, evaluate their possible applications as clinical biomarkers and therapeutic targets, and provide a comprehensive overview of the ncRNAs regulatory network in PCa. We also identified ncRNAs that can be utilized as biomarkers for diagnosis, staging, grading and prognosis assessment in PCa. This review offers researchers a fresh perspective on the functions of exosomal ncRNAs in PCa and provides additional options for its diagnosis, progression monitoring, and prognostic prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.